



ALVION

Product Portfolio

2024 / 2025

Alvion Pharmaceuticals P.C.
91, Marathonos Ave. & 2, Elaionon St.
Pallini, 153 51 - Athens, Greece
Tel.: +30 210 7101 660
bd@alvionpharma.com
www.alvionpharma.com

Alvion Ireland Limited
Galway Technology Centre
Mervue Business Park, Galway
H91 D932, Ireland
Tel: +353 9170 4821
bd@alvionpharma.com
www.alvionpharma.com



PRODUCT LIST 2024 / 2025

| CAT. | PRODUCT | PHARMACEUTICAL FORM | STRENGTHS | THERAPEUTIC CATEGORY | REFERENCE | DOSSIER STATUS |
|------------------|----------------------------|---------------------|--|---|--------------------|----------------|
| Cardiology | Bempedoic acid | Film Coated Tablets | 180mg | Refractory hypercholesterolemia | Nexletol® | Q2/2025 |
| | Bempedoic acid + Ezetimibe | Film Coated Tablets | 180mg + 10mg | Refractory hypercholesterolemia | Nexlizet® | Q3/2025 |
| | Sacubitril + Valsartan | Film Coated Tablets | 24mg + 26mg 49mg+51mg 97mg+103mg | Chronic heart failure | Entresto® | Q1/2026 |
| | Rosuvastatin + Ezetimibe | Film Coated Tablets | 5mg + 10mg 10mg + 10mg 20mg + 10mg 40mg + 10mg | Cholesterol and triglyceride regulator | Crestor®+ Ezetrol® | Launched |
| | Atorvastatin + Ezetimibe | Film Coated Tablets | 10mg + 10mg 20mg + 10mg 40mg + 10mg 80mg + 10mg | Cholesterol and triglyceride regulator | Atozet® | Launched |
| | Apixaban | Film Coated Tablets | 2.5mg, 5mg | Oral anticoagulant | Eliquis® | Completed |
| | Apixaban | Oral Solution | 1mg/ml | Anticoagulant | Eliquis® | Q2/2025 |
| | Ticagrelor | Film Coated Tablets | 60mg / 90mg | Antithrombotic | Brilique® | Completed |
| | Rivaroxaban | Film Coated Tablets | 2.5mg, 10mg, 15mg, 20mg | Oral anticoagulant | Xarelto® | Launched |
| | CNS | Vortioxetine | Film Coated Tablets | 5mg 10mg 15mg 20mg | Antidepressant | Brintellix® |
| Lisdexamfetamine | | Capsules | 20mg, 30mg, 40mg 50mg, 60mg, 70mg | Attention deficit hyperactivity disorder (ADHD) | Vyvanse® | Q4/2024 |
| Cariprazine | | Hard Capsules | 1.5mg, 3mg, 4.5mg, 6mg | Schizophrenia | Reagila® | Q1/2026 |
| Oncology | Lenvatinib | Capsules | 4mg 10mg | Renal cell carcinoma and Hepatocellular carcinoma | Lenvina®/ Kisplyx® | Q3/2025 |
| | Apalutamide | Film Coated Tablets | 60mg, 240mg | Prostate cancer | Erleada® | Q2/2026 |

| CAT. | PRODUCT | PHARMACEUTICAL FORM | STRENGTHS | THERAPEUTIC CATEGORY | REFERENCE | DOSSIER STATUS |
|--------------------------|---------------------------------------|---------------------|--|----------------------------|-----------------------|----------------|
| Diabetes | Dapagliflozin | Film Coated Tablets | 5mg 10mg | Oral Antidiabetic | Forxiga® | Completed |
| | Dapagliflozin + Metformin | Film Coated Tablets | 5mg + 850mg 5mg + 1000mg | Oral Antidiabetic | Xigduo® | Q4/2024 |
| | Dapagliflozin + Metformin XR | Film Coated Tablets | 5mg + 500mg 5mg + 1000mg 10mg + 500mg 10mg + 1000mg | Oral Antidiabetic | Xigduo XR® | Q2/2025 |
| | Empagliflozin | Film Coated Tablets | 10mg 25mg | Oral Antidiabetic | Jardiance® | Q1/2025 |
| | Empagliflozin + Metformin | Film Coated Tablets | 5mg + 850mg 5mg + 1000mg 12.5mg + 850mg 12.5mg + 1000mg | Oral Antidiabetic | Synjardy® | Q2/2025 |
| | Empagliflozin + Linagliptin | Film Coated Tablets | 10mg+5mg 25mg+5mg | Oral Antidiabetic | Glyxambi® | Q4/2025 |
| | Sitagliptin Hydrochloride | Film Coated Tablets | 25mg 50mg 100mg | Oral Antidiabetic | Januvia® | Launched |
| | Sitagliptin Hydrochloride + Metformin | Film Coated Tablets | 50mg+850mg 50mg+1000mg | Oral Antidiabetic | Janumet® | Launched |
| | Sitagliptin + Metformin XR | Film Coated Tablets | 50mg+500mg 50mg+1000mg 100mg+1000mg | Oral Antidiabetic | Janumet® XR | Launched |
| | Urology | Mirabegron PR | Prolonged released f.c. tablets | 25mg, 50mg | Urinary antispasmodic | Betmiga® |
| Mirabegron + Solifenacin | | Film Coated Tablets | 25mg + 5mg 50mg + 5mg | Urinary antispasmodic | Betmiga®/ Vesicare® | Q3/2025 |
| | Desmopressin | Sublingual Tablets | 60mcg 120mcg 240mcg | Primary Nocturnal Enuresis | Minirin® | Launched |

